Quantifying the Impact of Prostate Volumes, Number of Biopsy Cores and 5α-Reductase Inhibitor Therapy on the Probability of Prostate Cancer Detection Using Mathematical Modeling

Robert Serfling, Michael Shulman, G. L. Thompson, Zhiyao Xiao, Elie Benaim, Claus Roehrborn, Roger Rittmaster

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: Previous studies demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial. Materials and Methods: A mathematical model was constructed to analyze the effects of prostate and tumor volumes, and biopsy core number on cancer detection. The effects of the volume reduction observed with finasteride in the Prostate Cancer Prevention Trial were also modeled, as was the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection. The model was also applied to the Reduction by Dutasteride of Prostate Cancer Events study. Results: A higher number of biopsies are required to ensure a detection probability of 0.90 or greater in larger glands or with smaller tumors. In the Prostate Cancer Prevention Trial for a tumor volume of 1 cc a 17% increase in the detection rate in the finasteride arm would be predicted if there was no change in tumor volume, likewise the rate would be 11% to 17% for the dutasteride arm of the Reduction by Dutasteride of Prostate Cancer Events study. The calculated reduction in tumor volume needed to explain the difference in cancer detection between the finasteride and placebo arms of the Prostate Cancer Prevention Trial would be 51% to 66%. Conclusions: This model provides guidance on the optimal number of biopsy cores that accord with an earlier model. These findings also suggest that, if there were no reduction in tumor volume, 5α-reductase inhibitor therapy could lead to excess cancer detection, including high grade tumors.

Original languageEnglish (US)
Pages (from-to)2352-2356
Number of pages5
JournalJournal of Urology
Volume177
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Tumor Burden
Prostate
Prostatic Neoplasms
Oxidoreductases
Finasteride
Biopsy
Neoplasms
Therapeutics
Theoretical Models
Placebos
Dutasteride

Keywords

  • androgens
  • biopsy
  • decision support techniques
  • prostate
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Quantifying the Impact of Prostate Volumes, Number of Biopsy Cores and 5α-Reductase Inhibitor Therapy on the Probability of Prostate Cancer Detection Using Mathematical Modeling. / Serfling, Robert; Shulman, Michael; Thompson, G. L.; Xiao, Zhiyao; Benaim, Elie; Roehrborn, Claus; Rittmaster, Roger.

In: Journal of Urology, Vol. 177, No. 6, 06.2007, p. 2352-2356.

Research output: Contribution to journalArticle

Serfling, Robert ; Shulman, Michael ; Thompson, G. L. ; Xiao, Zhiyao ; Benaim, Elie ; Roehrborn, Claus ; Rittmaster, Roger. / Quantifying the Impact of Prostate Volumes, Number of Biopsy Cores and 5α-Reductase Inhibitor Therapy on the Probability of Prostate Cancer Detection Using Mathematical Modeling. In: Journal of Urology. 2007 ; Vol. 177, No. 6. pp. 2352-2356.
@article{ea6115012d034f96b3887c4123c5ed9f,
title = "Quantifying the Impact of Prostate Volumes, Number of Biopsy Cores and 5α-Reductase Inhibitor Therapy on the Probability of Prostate Cancer Detection Using Mathematical Modeling",
abstract = "Purpose: Previous studies demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial. Materials and Methods: A mathematical model was constructed to analyze the effects of prostate and tumor volumes, and biopsy core number on cancer detection. The effects of the volume reduction observed with finasteride in the Prostate Cancer Prevention Trial were also modeled, as was the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection. The model was also applied to the Reduction by Dutasteride of Prostate Cancer Events study. Results: A higher number of biopsies are required to ensure a detection probability of 0.90 or greater in larger glands or with smaller tumors. In the Prostate Cancer Prevention Trial for a tumor volume of 1 cc a 17{\%} increase in the detection rate in the finasteride arm would be predicted if there was no change in tumor volume, likewise the rate would be 11{\%} to 17{\%} for the dutasteride arm of the Reduction by Dutasteride of Prostate Cancer Events study. The calculated reduction in tumor volume needed to explain the difference in cancer detection between the finasteride and placebo arms of the Prostate Cancer Prevention Trial would be 51{\%} to 66{\%}. Conclusions: This model provides guidance on the optimal number of biopsy cores that accord with an earlier model. These findings also suggest that, if there were no reduction in tumor volume, 5α-reductase inhibitor therapy could lead to excess cancer detection, including high grade tumors.",
keywords = "androgens, biopsy, decision support techniques, prostate, prostatic neoplasms",
author = "Robert Serfling and Michael Shulman and Thompson, {G. L.} and Zhiyao Xiao and Elie Benaim and Claus Roehrborn and Roger Rittmaster",
year = "2007",
month = "6",
doi = "10.1016/j.juro.2007.01.116",
language = "English (US)",
volume = "177",
pages = "2352--2356",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Quantifying the Impact of Prostate Volumes, Number of Biopsy Cores and 5α-Reductase Inhibitor Therapy on the Probability of Prostate Cancer Detection Using Mathematical Modeling

AU - Serfling, Robert

AU - Shulman, Michael

AU - Thompson, G. L.

AU - Xiao, Zhiyao

AU - Benaim, Elie

AU - Roehrborn, Claus

AU - Rittmaster, Roger

PY - 2007/6

Y1 - 2007/6

N2 - Purpose: Previous studies demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial. Materials and Methods: A mathematical model was constructed to analyze the effects of prostate and tumor volumes, and biopsy core number on cancer detection. The effects of the volume reduction observed with finasteride in the Prostate Cancer Prevention Trial were also modeled, as was the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection. The model was also applied to the Reduction by Dutasteride of Prostate Cancer Events study. Results: A higher number of biopsies are required to ensure a detection probability of 0.90 or greater in larger glands or with smaller tumors. In the Prostate Cancer Prevention Trial for a tumor volume of 1 cc a 17% increase in the detection rate in the finasteride arm would be predicted if there was no change in tumor volume, likewise the rate would be 11% to 17% for the dutasteride arm of the Reduction by Dutasteride of Prostate Cancer Events study. The calculated reduction in tumor volume needed to explain the difference in cancer detection between the finasteride and placebo arms of the Prostate Cancer Prevention Trial would be 51% to 66%. Conclusions: This model provides guidance on the optimal number of biopsy cores that accord with an earlier model. These findings also suggest that, if there were no reduction in tumor volume, 5α-reductase inhibitor therapy could lead to excess cancer detection, including high grade tumors.

AB - Purpose: Previous studies demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial. Materials and Methods: A mathematical model was constructed to analyze the effects of prostate and tumor volumes, and biopsy core number on cancer detection. The effects of the volume reduction observed with finasteride in the Prostate Cancer Prevention Trial were also modeled, as was the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection. The model was also applied to the Reduction by Dutasteride of Prostate Cancer Events study. Results: A higher number of biopsies are required to ensure a detection probability of 0.90 or greater in larger glands or with smaller tumors. In the Prostate Cancer Prevention Trial for a tumor volume of 1 cc a 17% increase in the detection rate in the finasteride arm would be predicted if there was no change in tumor volume, likewise the rate would be 11% to 17% for the dutasteride arm of the Reduction by Dutasteride of Prostate Cancer Events study. The calculated reduction in tumor volume needed to explain the difference in cancer detection between the finasteride and placebo arms of the Prostate Cancer Prevention Trial would be 51% to 66%. Conclusions: This model provides guidance on the optimal number of biopsy cores that accord with an earlier model. These findings also suggest that, if there were no reduction in tumor volume, 5α-reductase inhibitor therapy could lead to excess cancer detection, including high grade tumors.

KW - androgens

KW - biopsy

KW - decision support techniques

KW - prostate

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=34248138901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248138901&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.01.116

DO - 10.1016/j.juro.2007.01.116

M3 - Article

VL - 177

SP - 2352

EP - 2356

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -